MX2016010215A - Composiciones y metodos de tratamiento y prevencion de degeneracion macular. - Google Patents

Composiciones y metodos de tratamiento y prevencion de degeneracion macular.

Info

Publication number
MX2016010215A
MX2016010215A MX2016010215A MX2016010215A MX2016010215A MX 2016010215 A MX2016010215 A MX 2016010215A MX 2016010215 A MX2016010215 A MX 2016010215A MX 2016010215 A MX2016010215 A MX 2016010215A MX 2016010215 A MX2016010215 A MX 2016010215A
Authority
MX
Mexico
Prior art keywords
methods
compositions
macular degeneration
treating
preventing macular
Prior art date
Application number
MX2016010215A
Other languages
English (en)
Spanish (es)
Inventor
Scaria Abraham
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2016010215A publication Critical patent/MX2016010215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
    • H02J50/10—Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
    • H02J50/40—Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/0013—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries acting upon several batteries simultaneously or sequentially
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/0042—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by the mechanical construction
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/0042—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by the mechanical construction
    • H02J7/0045—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by the mechanical construction concerning the insertion or the connection of the batteries
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/02—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries for charging batteries from AC mains by converters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/34—Parallel operation in networks using both storage and other DC sources, e.g. providing buffering
    • H02J7/35—Parallel operation in networks using both storage and other DC sources, e.g. providing buffering with light sensitive cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Power Engineering (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2016010215A 2014-02-06 2015-02-06 Composiciones y metodos de tratamiento y prevencion de degeneracion macular. MX2016010215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936797P 2014-02-06 2014-02-06
PCT/US2015/014872 WO2015120309A1 (en) 2014-02-06 2015-02-06 Compositions and methods for treating and preventing macular degeneration

Publications (1)

Publication Number Publication Date
MX2016010215A true MX2016010215A (es) 2016-11-15

Family

ID=52589781

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010215A MX2016010215A (es) 2014-02-06 2015-02-06 Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
MX2023011453A MX2023011453A (es) 2014-02-06 2016-08-05 Composiciones para usarse en el tratamiento y prevencion de degeneracion macular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011453A MX2023011453A (es) 2014-02-06 2016-08-05 Composiciones para usarse en el tratamiento y prevencion de degeneracion macular.

Country Status (14)

Country Link
US (2) US20170007719A1 (cg-RX-API-DMAC7.html)
EP (1) EP3102246B1 (cg-RX-API-DMAC7.html)
JP (1) JP6719381B2 (cg-RX-API-DMAC7.html)
KR (1) KR102234695B1 (cg-RX-API-DMAC7.html)
CN (3) CN120131999A (cg-RX-API-DMAC7.html)
AU (4) AU2015213770A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016017817A2 (cg-RX-API-DMAC7.html)
CA (1) CA2938828A1 (cg-RX-API-DMAC7.html)
IL (1) IL247116B (cg-RX-API-DMAC7.html)
MX (2) MX2016010215A (cg-RX-API-DMAC7.html)
RU (1) RU2703145C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201606101WA (cg-RX-API-DMAC7.html)
TW (1) TWI687225B (cg-RX-API-DMAC7.html)
WO (1) WO2015120309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2703145C2 (ru) 2014-02-06 2019-10-15 Джензим Корпорейшн Композиции и способы лечения и предотвращения дегенерации желтого пятна
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
MX2019011040A (es) 2017-03-17 2020-01-20 Adverum Biotechnologies Inc Composiciones y metodos para potenciar la expresion genica.
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
JP2021513355A (ja) * 2018-02-14 2021-05-27 ジェネレーション バイオ カンパニー 非ウイルス性ｄｎａベクター、ならびに抗体および融合タンパク質の産生のためのその使用
CN113365603B (zh) * 2018-10-11 2025-04-11 分贝治疗公司 Aav1载体及其用于治疗耳部适应症的用途
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
WO2025061000A1 (zh) * 2023-09-21 2025-03-27 成都弘基生物科技有限公司 一种用于治疗受试者中与血管新生相关的眼病的方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
IL147270A0 (en) 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
CA2410828C (en) 2000-06-01 2012-01-24 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP1490113A4 (en) 2002-03-20 2007-05-02 Univ Florida RAAV VECTOR COMPOSITIONS AND METHOD FOR TREATING CHOROIDAL NEOVASCULARIZATION
WO2004079332A2 (en) 2003-03-04 2004-09-16 National Institute Of Advanced Industrial Science And Technology Composition and method for increasing efficiency of introduction of target substance into cell
ES2521682T3 (es) 2003-05-21 2014-11-13 Genzyme Corporation Procedimientos para producir preparaciones de viriones de AAV recombinantes sustancialmente exentas de cápsidas vacías
CN100516401C (zh) * 2003-08-04 2009-07-22 邱则有 一种现浇砼用空腔模壳构件
US7378095B2 (en) 2004-07-30 2008-05-27 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PT2229956E (pt) 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
WO2006056823A1 (en) * 2004-11-26 2006-06-01 Novagali Pharma Sa Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2203476B1 (en) 2007-09-25 2016-10-26 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
WO2009073551A2 (en) 2007-11-30 2009-06-11 Scarab Genomics Llc Lac expression system
JP2011512417A (ja) 2008-02-20 2011-04-21 ジェンザイム・コーポレーション 血管形成の阻害
US20100081707A1 (en) 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
SG10201403290SA (en) 2009-06-16 2014-10-30 Genzyme Corp Improved methods for purification of recombinant aav vectors
EP2553106A2 (en) 2010-03-29 2013-02-06 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9102718B2 (en) 2010-04-30 2015-08-11 Lpath, Inc. Anti-S1P antibody treatment of patients with ocular disease
TWI702955B (zh) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
CN105682674A (zh) 2013-04-17 2016-06-15 建新公司 用于治疗和预防黄斑变性的组合物和方法
RU2703145C2 (ru) 2014-02-06 2019-10-15 Джензим Корпорейшн Композиции и способы лечения и предотвращения дегенерации желтого пятна

Also Published As

Publication number Publication date
AU2015213770A1 (en) 2016-09-01
IL247116B (en) 2020-06-30
SG11201606101WA (en) 2016-08-30
TW201542217A (zh) 2015-11-16
CN111068072A (zh) 2020-04-28
AU2025203206A1 (en) 2025-05-29
MX2023011453A (es) 2023-10-18
TWI687225B (zh) 2020-03-11
CA2938828A1 (en) 2015-08-13
RU2016135771A (ru) 2018-03-14
RU2016135771A3 (cg-RX-API-DMAC7.html) 2018-10-15
BR112016017817A2 (pt) 2017-10-10
JP2017506230A (ja) 2017-03-02
JP6719381B2 (ja) 2020-07-08
EP3102246B1 (en) 2020-03-25
CN120131999A (zh) 2025-06-13
KR20160110523A (ko) 2016-09-21
US20220288232A1 (en) 2022-09-15
AU2021250986B2 (en) 2025-02-06
EP3102246A1 (en) 2016-12-14
IL247116A0 (en) 2016-09-29
KR102234695B1 (ko) 2021-04-02
US12483047B2 (en) 2025-11-25
US20170007719A1 (en) 2017-01-12
AU2019203413A1 (en) 2019-06-06
AU2021250986A1 (en) 2021-11-18
RU2703145C2 (ru) 2019-10-15
AU2019203413B2 (en) 2021-07-15
WO2015120309A1 (en) 2015-08-13
CN106163573A (zh) 2016-11-23

Similar Documents

Publication Publication Date Title
MX2016010215A (es) Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
HUE049341T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
IL252159B (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
IL252943A0 (en) Sunitinib formulations and methods of using them for the treatment of eye diseases
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
UY36021A (es) Proteìnas fc multimèricas
NZ737399A (en) Ccr2 modulators
PH12017500164A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
MX2016010953A (es) Proteinas de fc multimericas.
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CL2015002835A1 (es) Nuevos derivados de piridina
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
PH12015502469A1 (en) Fcrn-binding abolished anti-igf-ir antibodies and their use in the treatment of vascular eye diseases
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
PH12017500602A1 (en) Methods for treating ocular conditions
BR112017023762A2 (pt) formulações de depósito injetáveis
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
MX2016011706A (es) Formulaciones de progesterona.
EA201700074A1 (ru) Стабильные не содержащие консерванты офтальмологические составы опиоидных антагонистов